.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,114,355

« Back to Dashboard

Details for Patent: 6,114,355

Title: Methods and compositions for inhibition of angiogenesis
Abstract:The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
Inventor(s): D'Amato; Robert (Lancaster, PA)
Assignee:
Filing Date:Jul 30, 1998
Application Number:09/126,542
Claims:1. A method of treating undesired angiogenesis associated with ocular neovascular diseases, choroidal neovascular diseases, retina neovascular diseases, neovascularization of the angle, Bartonellosis, chronic inflammation, osteoarthritis, atherosclerosis phemphigoid, trachoma, or Osler-Webber-Rendu disease in a human comprising administering an angiogenesis inhibiting amount of thalidomide to the human wherein the undesired angiogenesis is not associated with a solid or blood-born tumor.

2. The method of claim 1 wherein the undesired angiogenesis occurs in diabetic retinopathy.

3. The method of claim 1 wherein the undesired angiogenesis occurs in retinopathy of prematurity.

4. The method of claim 1 wherein the undesired angiogenesis occurs in corneal graft rejection.

5. The method of claim 1 wherein the undesired angiogenesis occurs in neovascular glaucoma.

6. The method of claim 1 wherein the undesired angiogenesis occurs in retrolental fibroplasia.

7. The method of claim 1 wherein the undesired angiogenesis occurs in epidemic keratoconjunctivitis.

8. The method of claim 1 wherein the undesired angiogenesis occurs due to contact lens overwear.

9. The method of claim 1 wherein the undesired angiogenesis occurs in Terrien's marginal degeneration.

10. The method of claim 1 wherein the undesired angiogenesis occurs in radial keratotomy.

11. The method of claim 1 wherein the undesired angiogenesis occurs in macular degeneration.

12. The method of claim 1 wherein the undesired angiogenesis occurs in scleritis.

13. The method of claim 1 wherein the undesired angiogenesis occurs in chronic uveitis.

14. The method of claim 1 wherein the undesired angiogenesis occurs in chronic vitritis.

15. The method of claim 1 wherein the undesired angiogenesis occurs in myopia.

16. The method of claim 1 wherein the undesired angiogenesis occurs in optic pits.

17. The method of claim 1 wherein the undesired angiogenesis occurs in chronic retinal detachment.

18. The method of claim 1 wherein the undesired angiogenesis occurs in hyperviscosity syndromes.

19. The method of claim 1 wherein the undesired angiogenesis occurs in infections causing retinitis or choroiditis.

20. The method of claim 1 wherein the undesired angiogenesis occurs in presumed ocular histoplasmosis.

21. The method of claim 1 wherein the undesired angiogenesis occurs in proliferative vitreoretinopathy.

22. The method of claim 1 wherein the undesired angiogenesis occurs in trachoma.

23. The method of claim 1 wherein the undesired angiogenesis occurs due to Vitamin A deficiency.

24. The method of claim 1 wherein the undesired angiogenesis occurs in phylectenulosis.

25. The method of claim 1 wherein the undesired angiogenesis occurs in syphilis.

26. The method of claim 1 wherein the undesired angiogenesis occurs in lipid degeneration.

27. The method of claim 1 wherein the undesired angiogenesis occurs in bacterial ulcers.

28. The method of claim 1 wherein the undesired angiogenesis occurs in fungal ulcers.

29. The method of claim 1 wherein the undesired angiogenesis occurs in Mooren's ulcer.

30. The method of claim 1 wherein the undesired angiogenesis occurs in Stevens-Johnson disease.

31. The method of claim 1 wherein the undesired angiogenesis occurs in protozoan infections.

32. The method of claim 1 wherein the undesired angiogenesis is caused by trauma.

33. The method of claim 1 wherein the undesired angiogenesis occurs in chemical burns.

34. The method of claim 1 wherein the undesired angiogenesis occurs in polyarteritis.

35. The method of claim 1 wherein the undesired angiogenesis occurs in vein occlusion.

36. The method of claim 1 wherein the undesired angiogenesis occurs in artery occlusion.

37. The method of claim 1 wherein the undesired angiogenesis occurs in carotid obstructive disease.

38. The method of claim 1 wherein the undesired angiogenesis occurs in sickle cell anemia.

39. The method of claim 1 wherein the undesired angiogenesis occurs in pseudoxanthoma elasticum.

40. The method of claim 1 wherein the undesired angiogenesis occurs in Paget's disease.

41. The method of claim 1 wherein the undesired angiogenesis occurs in Lyme's disease.

42. The method of claim 1 wherein the undesired angiogenesis occurs in Eales' disease.

43. The method of claim 1 wherein the undesired angiogenesis occurs in Stargardt's disease.

44. The method of claim 1 wherein the undesired angiogenesis occurs in pars planitis.

45. The method of claim 1 wherein the undesired angiogenesis occurs in toxoplasmosis.

46. The method of claim 1 wherein the undesired angiogenesis occurs in post-laser complications.

47. The method of claim 1 wherein the undesired angiogenesis occurs due to abnormal proliferation of fibrovascular or fibrous tissue.

48. The method of claim 1 wherein the undesired angiogenesis occurs in Osler-Weber-Rendu disease.

49. The method of claim 1 wherein the undesired angiogenesis occurs in ocular neovascular disease.

50. The method of claim 1 wherein the undesired angiogenesis occurs in age-related macular degeneration.

51. The method of claim 1 wherein the undesired angiogenesis occurs in osteoarthritis.

52. The method of claim 1 wherein the undesired angiogenesis occurs in Crohn's disease.

53. The method of claim 1 wherein the undesired angiogenesis occurs in atherosclerosis.

54. The method of claim 1 wherein the undesired angiogenesis occurs in pemphigoid.

55. The method of claim 1 wherein the undesired angiogenesis occurs in Best's disease.

56. The method of claim 1 wherein the undesired angiogenesis occurs in Bartonellosis.

57. A method of treating undesired angiogenesis associated with ocular neovascular diseases, choroidal neovascular diseases, retinal neovascular diseases, neovascularization of the angle, Bartonellosis, osteoarthritis, atherosclerosis, phemphigoid, trachoma, or Osler-Webber-Rendu disease in an animal comprising administering an angiogenesis inhibiting amount of thalidomide to the animal, wherein the undesired angiogenesis is not associated with a solid or blood-born tumor.

58. The method of claim 57 wherein the undesired angiogenesis occurs in diabetic retinopathy.

59. The method of claim 57 wherein the undesired angiogenesis occurs in retinopathy of prematurity.

60. The method of claim 57 wherein the undesired angiogenesis occurs in corneal graft rejection.

61. The method of claim 57 wherein the undesired angiogenesis occurs in neovascular glaucoma.

62. The method of claim 57 wherein the undesired angiogenesis occurs in retrolental fibroplasia.

63. The method of claim 57 wherein the undesired angiogenesis occurs in epidemic keratoconjunctivitis.

64. The method of claim 57 wherein the undesired angiogenesis occurs due to contact lens overwear.

65. The method of claim 57 wherein the undesired angiogenesis occurs in Terrien's marginal degeneration.

66. The method of claim 57 wherein the undesired angiogenesis occurs in radial keratotomy.

67. The method of claim 57 wherein the undesired angiogenesis occurs in macular degeneration.

68. The method of claim 57 wherein the undesired angiogenesis occurs in scleritis.

69. The method of claim 57 wherein the undesired angiogenesis occurs in chronic uveitis.

70. The method of claim 57 wherein the undesired angiogenesis occurs in chronic vitritis.

71. The method of claim 57 wherein the undesired angiogenesis occurs in myopia.

72. The method of claim 57 wherein the undesired angiogenesis occurs in optic pits.

73. The method of claim 57 wherein the undesired angiogenesis occurs in chronic retinal detachment.

74. The method of claim 57 wherein the undesired angiogenesis occurs in hyperviscosity syndromes.

75. The method of claim 57 wherein the undesired angiogenesis occurs in infections causing retinitis or choroiditis.

76. The method of claim 57 wherein the undesired angiogenesis occurs in presumed ocular histoplasmosis.

77. The method of claim 57 wherein the undesired angiogenesis occurs in proliferative vitreoretinopathy.

78. The method of claim 57 wherein the undesired angiogenesis occurs in trachoma.

79. The method of claim 57 wherein the undesired angiogenesis occurs due to Vitamin A deficiency.

80. The method of claim 57 wherein the undesired angiogenesis occurs in phylectenulosis.

81. The method of claim 57 wherein the undesired angiogenesis occurs in syphilis.

82. The method of claim 57 wherein the undesired angiogenesis occurs in lipid degeneration.

83. The method of claim 57 wherein the undesired angiogenesis occurs in bacterial ulcers.

84. The method of claim 57 wherein the undesired angiogenesis occurs in fungal ulcers.

85. The method of claim 57 wherein the undesired angiogenesis occurs in Mooren's ulcer.

86. The method of claim 57 wherein the undesired angiogenesis occurs in Stevens-Johnson disease.

87. The method of claim 57 wherein the undesired angiogenesis occurs in protozoan infections.

88. The method of claim 57 wherein the undesired angiogenesis is caused by trauma.

89. The method of claim 57 wherein the undesired angiogenesis occurs in chemical burns.

90. The method of claim 57 wherein the undesired angiogenesis occurs in polyarteritis.

91. The method of claim 57 wherein the undesired angiogenesis occurs in vein occlusion.

92. The method of claim 57 wherein the undesired angiogenesis occurs in artery occlusion.

93. The method of claim 57 wherein the undesired angiogenesis occurs in carotid obstructive disease.

94. The method of claim 57 wherein the undesired angiogenesis occurs in sickle cell anemia.

95. The method of claim 57 wherein the undesired angiogenesis occurs in pseudoxanthoma elasticum.

96. The method of claim 57 wherein the undesired angiogenesis occurs in Paget's disease.

97. The method of claim 57 wherein the undesired angiogenesis occurs in Lyme's disease.

98. The method of claim 57 wherein the undesired angiogenesis occurs in Eales' disease.

99. The method of claim 57 wherein the undesired angiogenesis occurs in Stargardt's disease.

100. The method of claim 57 wherein the undesired angiogenesis occurs in pars planitis.

101. The method of claim 57 wherein the undesired angiogenesis occurs in toxoplasmosis.

102. The method of claim 57 wherein the undesired angiogenesis occurs in post-laser complications.

103. The method of claim 57 wherein the undesired angiogenesis occurs due to abnormal proliferation of fibrovascular or fibrous tissue.

104. The method of claim 57 wherein the undesired angiogenesis occurs in Osler-Weber-Rendu disease.

105. The method of claim 57 wherein the undesired angiogenesis occurs in ocular neovascular disease.

106. The method of claim 57 wherein the undesired angiogenesis occurs in age-related macular degeneration.

107. The method of claim 57 wherein the undesired angiogenesis occurs in osteoarthritis.

108. The method of claim 57 wherein the undesired angiogenesis occurs in Crohn's disease.

109. The method of claim 57 wherein the undesired angiogenesis occurs in atherosclerosis.

110. The method of claim 57 wherein the undesired angiogenesis occurs in pemphigoid.

111. The method of claim 57 wherein the undesired angiogenesis occurs in Best's disease.

112. The method of claim 57 wherein the undesired angiogenesis occurs in Bartonellosis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc